Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has received an average rating of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $6.50.
IPSC has been the subject of a number of analyst reports. Piper Sandler reduced their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Century Therapeutics in a report on Wednesday, January 22nd. Finally, Guggenheim reissued a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd.
View Our Latest Research Report on IPSC
Institutional Investors Weigh In On Century Therapeutics
Century Therapeutics Stock Up 6.8 %
NASDAQ IPSC opened at $0.60 on Thursday. The stock has a market capitalization of $50.70 million, a PE ratio of -0.32 and a beta of 1.75. The company has a 50 day moving average price of $0.79 and a two-hundred day moving average price of $1.20. Century Therapeutics has a 12-month low of $0.55 and a 12-month high of $5.24.
Century Therapeutics Company Profile
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Featured Stories
- Five stocks we like better than Century Therapeutics
- Trading Halts Explained
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Most Volatile Stocks, What Investors Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Nasdaq? Complete Overview with History
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.